Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis


Current price
1.63 USD +0.06 USD (+3.82%)
Last closed 1.56 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 134 675 968 USD
Yield for 12 month -56.06 %
21.11.2021 - 28.11.2021

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. Address: New Bund Center, Shanghai, China, 200124


WallStreet Target Price

33.33 USD

P/E ratio

Dividend Yield

Current Year

-31 329 610 USD

Last Year

+12 447 115 USD

Current Quarter

-249 467 053 USD

Last Quarter

Current Year

-35 180 995 USD

Last Year

+5 881 505 USD

Current Quarter

-253 318 439 USD

Last Quarter

Key Figures IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -1 859 417 984 USD
Operating Margin TTM -3417.82 %
PE Ratio
Return On Assets TTM -25.36 %
PEG Ratio
Return On Equity TTM -66.16 %
Wall Street Target Price 33.33 USD
Revenue TTM -253 766 000 USD
Book Value 29.48 USD
Revenue Per Share TTM -3.06 USD
Dividend Share
Quarterly Revenue Growth YOY -62.1 %
Dividend Yield
Gross Profit TTM 41 594 000 USD
Earnings Share -3.79 USD
Diluted Eps TTM -3.79 USD
Most Recent Quarter I 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IMAB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.0615
Price Sales TTM 2.5452
Enterprise Value EBITDA 0.1207
Price Book MRQ 0.3907

Financials IMAB

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IMAB

For 52 weeks

1.16 USD 7.67 USD
50 Day MA 1.44 USD
Shares Short Prior Month 1 908 565
200 Day MA 2.61 USD
Short Ratio 3.21
Shares Short 1 912 441
Short Percent 2.94 %